ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0836

NF-κB Inducing Kinase Is a Therapeutic Target for Autoimmune Diseases by Orchestrating Both B Cell and T Follicular Helper Cell Responses

Jee Ho Lee1, Manisha Mohandoss2, Lichchavi Rajasinghe1, Silvia Preite3, Katie Madore2, Mark Birrell4, Jan Piet van Hamburg5, Sander Tas6, Matthew Perry3, Tatiana Ort1 and Gary Sims1, 1Immunology Biosciences, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, 2Immunology Biosciences, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gaitherburg, 3Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, 4Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, london, United Kingdom, 5Amsterdam UMC, Amsterdam, Netherlands, 6Amsterdam UMC, locatie AMC, Amsterdam, Netherlands

Meeting: ACR Convergence 2024

Keywords: autoimmune diseases, B-Lymphocyte, Cell-signalling molecules, T-Lymphocyte

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 16, 2024

Title: Abstracts: T Cell Biology & Targets in Autoimmune & Inflammatory Disease

Session Type: Abstract Session

Session Time: 3:00PM-4:30PM

Background/Purpose: T follicular helper (Tfh) cells are a specialized CD4+ T cell subset which can help B cells in the germinal center (GC) to drive B cell differentiation and antibody production. Dysregulation of Tfh and/or B cells often leads to breakdown in tolerance and development of autoimmunity. NF-κB inducing kinase (NIK) regulates immune cell signaling downstream of a subset of the tumor necrosis factor superfamily receptors including BAFFR, CD40, OX40, lymphotoxin receptor and RANK. It has been demonstrated that NIK is critical for B cell responses, but it is less clear how NIK regulates Tfh cell biology.

To investigate the role of NIK in CD70/CD27 signaling in the context of human Tfh cell differentiation and function by utilization of a small molecule NIK inhibitor in vitro and in vivo.

Methods: Human Tfh cells or plasma cells were generated with various ligands stimulating NIK induced NF-κB signaling. The proteolysis of p100 into p52 was examined by western blot to evaluate NIK activation. We performed flow cytometry, quantitative PCR, and ELISA to assess how NIK activation and/or inhibition impacted on Tfh development and plasma cell differentiation. B-T co-culture and 3D lymphoid organoid systems were adopted to examine the function of Tfh cells in B cell helping activity mimicking the GC response. We also used the OVA-immunization and collagen-induced arthritis mouse models in combination with small molecule NIK inhibition to establish a potential role of NIK in Tfh and plasma cell development during autoimmune disease progression.

Results: Stimulation by agonistic anti-CD27 antibodies promoted p52 processing from p100 in human primary T cells, indicating that CD27 activation results in NIK-dependent non-canonical NF-κB signaling. Interestingly, CD27-mediated NIK activation was able to induce IL-21-producing CXCR5+ ICOS+ PD-1+ CD40L+ Tfh cell differentiation, whereas it did not affect other T cell differentiation such as Th17 or Treg cells in vitro. Tfh cell development induced by CD27-NIK signaling was partially blocked by the small molecule NIK inhibitor, SMI1. Moreover, SMI1-treated Tfh cells were less potent in the induction of IgD– CD38hi CD27hi plasma cell differentiation and IgG production in both B-T co-cultures and GC organoids. This implies that the inhibition of NIK affects both T and B cells thereby achieving a huge potency in the suppression of inflammation. This was corroborated in the T cell-dependent immunization where administration of SMI1 reduced GC B cell responses and antigen specific antibody production, and ameliorated the progression of disease in collagen-induced arthritis models.

Conclusion: Our findings indicate that NIK-mediated signaling events play an intrinsic role in both Tfh and B cells to regulate immune responses. Targeting NIK may therefore have potential in the treatment of autoimmune diseases.


Disclosures: J. Lee: AstraZeneca, 3; M. Mohandoss: AstraZeneca, 3; L. Rajasinghe: AstraZeneca, 3; S. Preite: AstraZeneca, 3; K. Madore: AstraZeneca, 3; M. Birrell: AstraZeneca, 3; J. van Hamburg: None; S. Tas: None; M. Perry: AstraZeneca, 3; T. Ort: AstraZeneca, 3; G. Sims: AstraZeneca, 3.

To cite this abstract in AMA style:

Lee J, Mohandoss M, Rajasinghe L, Preite S, Madore K, Birrell M, van Hamburg J, Tas S, Perry M, Ort T, Sims G. NF-κB Inducing Kinase Is a Therapeutic Target for Autoimmune Diseases by Orchestrating Both B Cell and T Follicular Helper Cell Responses [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/nf-%ce%bab-inducing-kinase-is-a-therapeutic-target-for-autoimmune-diseases-by-orchestrating-both-b-cell-and-t-follicular-helper-cell-responses/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/nf-%ce%bab-inducing-kinase-is-a-therapeutic-target-for-autoimmune-diseases-by-orchestrating-both-b-cell-and-t-follicular-helper-cell-responses/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology